SEC Form 4 · accession 0000880771-17-000110
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Anthony Low
Officer — VP, Finance & Controller
Period of report
Jun 12, 2017
Accepted (ET)
Jun 14, 2017 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 12, 2017 | M | 1,250 | $0.00 | A | 15,536 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3,F4 | — | Jun 12, 2017 | M | 1,250 | D | — | — | Common Stock | 1,250 | 21,250 | D |
Explanation of responses
- F1Includes 773 shares purchased under the Issuer's Employee Purchase Plan on May 31, 2017.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F3Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F4Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.